The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Do Kim - Water Tower Research LLC - Analyst
: Great. Hi. Thanks for taking my questions, and congrats on the quarter's results. First, for Kirk, it seems that the strategic alliance with the sleep
clinic is pretty important in the evolution of Vivos Therapeutics. Could you maybe expand on that a little bit?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 14, 2024 / 9:00PM, VVOS.OQ - Q2 2024 Vivos Therapeutics Inc Earnings Call
And when you say that you're seeing -- you had previously reported experience in terms of like patients acceptance, are you referring to your
marketing pilot study and the high rate of patients that choose Vivos' oral appliances?
Question: Do Kim - Water Tower Research LLC - Analyst
: Yeah, you did. I mean a 70%, 80% conversion rate would mean an amazing opportunity for you guys. That's extraordinary. What do you see
happening with the VIP doctors or dentists that you've enrolled going forward?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 14, 2024 / 9:00PM, VVOS.OQ - Q2 2024 Vivos Therapeutics Inc Earnings Call
Question: Do Kim - Water Tower Research LLC - Analyst
: Okay, that makes sense. And just one quick question for Brad. Congrats on the cost-cutting efforts. It looks like it's really starting to reduce the cash
burn. Maybe you could provide a little more detail about what happened over the last several quarters to achieve this. And is there more room for
additional cost to come off?
Question: Do Kim - Water Tower Research LLC - Analyst
: Yes, absolutely. And it looks like it will pay off in the near future, hopefully. Great progress, guys. Thanks for taking my questions.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Thank you. Good afternoon, gentlemen, and congrats on your business progress.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 14, 2024 / 9:00PM, VVOS.OQ - Q2 2024 Vivos Therapeutics Inc Earnings Call
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: So I'm curious about -- it seems like a significant portion of the revenue jump was due to lower discounts. Brad mentioned 70% lower discounts
year on year. How does that come about? Was that just a unilateral policy, you just decided not to give them or did something in the business
model change to achieve that?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay. And then sort of similarly, you had a big sequential decline in sales commissions. So you're saving $300,000 or something sequentially. Like,
is that also a --
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay. With respect to overall operating expenses, which are now at $4.5 million, what do you see as a steady state for operating expenses because
they really went down a lot and they just keep going down?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay. All right, that's all I have. Thank you very much.
| 
